TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Parkinson's disease experience
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Symptoms of Parkinson's disease
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of failures linked to the procedure
Endpoint domain: Adverse events/effects
Primary endpoint: progression-free survival in months
Endpoint domain: Mortality/survival
Primary endpoint: incidence of major bleedings
Endpoint domain: Adverse events/effects
Primary endpoint: Ischemia-reperfusion damage
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Detection of sentinel nodes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Changes in the Kumamoto scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change From Baseline in Percent Predicted Forced Vital Capacity (FVC) at Week 52
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Change From Baseline in the Modified Rodnan Skin Score (mRSS) at Week 52/Early Termination
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Change From Baseline in UCLA SCTC GIT 2.0 Total Score at Week 52/Early Termination
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Maximum tolerated dose (MTD) of pemetrexed
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Compliance to feeding protocol
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Percentage of Participants With Clinical and Microbiological Cure: All Participants
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Percentage of Participants With Composite Cure: All Participants
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Body temperature monitoring
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of retrieved oocytes per procedure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Myocardial DFA uptake
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: CAPS Score Total
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: CAPS Score Intrusion
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Accuracy of magnetically guided capsule endoscopy (MGCE)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Complete or Stable Raymond Roy II
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Intracranial hemorrhage including SAH and IPH
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Neurological deaths
Endpoint domain: Mortality/survival
Primary endpoint: overall radiographic response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pharmacokinetics of Proellex and its metabolites
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: patient temperature below 34C within 4 hours
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: maintain patient target temperature for 24 hrs
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from baseline in PVR at Week 17
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Ablation Success
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Safety Endpoint
Endpoint domain: Adverse events/effects
Primary endpoint: Maximal Clot firmness (MCF)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Mean Positive Percentage Agreement for Fetal Heart
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Mean Positive Percentage Agreement for Maternal Heart
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Heart Rate Monitor Accuracy Compared to ECG
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Cardiovascular Effects
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Percentage of Participants with Clinically Significant Abnormalities in Clinical Laboratory Assessments
Endpoint domain: Adverse events/effects
Primary endpoint: Marginal bone loss around implant
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Number of Subjects Without Hospitalization for Ventricular Tachycardia (VT) During 6 Months
Endpoint domain: Mortality/survival
Primary endpoint: Number of Participants With No Serious Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Subjects Ablated for Nonsustained Arrhythmias Who Had a Reduction to Less Than 5000 Arrhythmia Beats Daily
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Reduction in skin damage
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Change From Baseline in Quantitative Hepatitis B Surface Antigen (HBsAG)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Distribution Volume (DV) of [11C]Donepezil
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Standard Uptake Value (SUV) of [11C]Donepezil
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pain scale - N-PASS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Histopathologic response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Ocular inflammation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Treatment effects
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Visual Analog Scale for Anxiety Scores
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Changes in resting surface EMG activity (amplitude, RMS) of the upper trapezius
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in EASI score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Number of Subjects Reporting Spatial Distortions Related to Intraocular Lens (IOL) Misalignment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction of Cylinder
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Lens Axis Misalignment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants with Pulmonary Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Sensitivity of the assay to detect HPV genotypes 16, 18 and/or 45
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Specificity of the assay to give a positive signal only in HPV 16, 18 and/or 45 positive samples
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Engagement in tobacco cessation treatment
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Reduction of discontinuation of Active Surveillance
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Changes in mass transport
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Patients Who Achieve Blood Pressure Control
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Incidence of Treatment-Emergent Adverse Events (AEs) - clinical laboratory abnormalities
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of Treatment-Emergent Adverse Events (AEs) - vital signs
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of Treatment-Emergent Adverse Events (AEs) - 12 lead ECG parameters
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of Treatment-Emergent Adverse Events (AEs) - physical examination
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of Treatment-Emergent Adverse Events (AEs) - skin score assessment
Endpoint domain: Adverse events/effects
Primary endpoint: OGS score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cesarean delivery scar cutaneous hyperalgesia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Contraceptive use at time of last sexual intercourse
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: Collated quality indicator score
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: AUCave of Relative Change in FEV1 % Predicted
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Change From Baseline in Lymphocyte Subsets Counts up to 48 Weeks: T Cell, B Cell, Natural Killer Cell (TBNK)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change From Baseline in Lymphocyte Subsets Counts up to 48 Weeks: T-Cells Subsets
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change From Baseline in Lymphocyte Subsets Counts up to 48 Weeks: B-Cell Subsets
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Exposure-adjusted Incidence Rates of Adverse Events of Special Interest
Endpoint domain: Adverse events/effects
Primary endpoint: EAIRs of Serious Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Postoperative pain after 7 days
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to first or only episode of clinical malaria
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: change in Arabic articulation test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: change in naso meter values
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: change in Auditory perceptual assessment of speech
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in systolic blood pressure levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Transplant-related mortality at 180 days
Endpoint domain: Mortality/survival
Primary endpoint: Improvement of right ventricular function (TAPSE)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Re-infection rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Overall Tumor Response Rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: 20 km time trial performance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clinical outcome
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Proportion of patients achieving excellent functional outcome
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Motor sequence task improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Psychomotor vigilance task lapse rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Serial reaction time test improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Visual discrimination task improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Oro-caecal transit time (OCTT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Cytokine levels in nasal lavage fluid
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Percentage of Participants With Adverse Events (AEs)/Adverse Drug Reactions (ADRs)
Endpoint domain: Adverse events/effects
Primary endpoint: Serious AEs/ADRs
Endpoint domain: Adverse events/effects
Primary endpoint: Unexpected AEs/ADRs
Endpoint domain: Adverse events/effects
Primary endpoint: Improvement in developmental skills
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in behavior
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: number of patients free from post stroke recurrent crisis
Endpoint domain: Mortality/survival
Primary endpoint: Return to physical activity/sports
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Knee function, IKDC
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: New injuries
Endpoint domain: Adverse events/effects
Primary endpoint: Vascular uptake measured by target-blood pool ratios (TBR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Change in Postural stability after treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in Biomechanics of gait after treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in biomechanics of stair climbing after treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Therapy Responder Rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With Seroconversion Response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Time to fever relief
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: number of positive Tourniquet Test results
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of preterm births
Endpoint domain: Mortality/survival
Primary endpoint: Proportion of patients with confirmed GHB poisoning
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Change in self-reported sugar-sweetened beverage consumption
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Changes of neuropsychiatric inventory (NPI) scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Mean of cortical SuVr
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Objective measurement of trans epidermal water loss of the skin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Objective measurement of the degree of erythema of the skin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: early neurological clinical recovery
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Levels of serum and urine metabolites
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: increase in volume of the future remnant liver (FRL)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: frequency of job exposure to endocrine disruptors
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: transferrin saturation (TSAT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in follicle stimulating hormone (FSH) levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Prevalence of Fabry mutations in patients with left ventricular hypertrophy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Composite Adverse Perinatal Outcome
Endpoint domain: Adverse events/effects
Primary endpoint: Small for Gestational Age
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: Change of sleep quality
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: Revocation rate
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Numbers Diagnosed With Gestational Diabetes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Radiographic Bone Level Mesial to the Implant
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Radiographic Bone Level Distal to the Implant
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Pleth Variability Index
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Minutes and Number of Disciplinary Time Out of Class Events
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Change in Conners Abbreviated Teacher Rating Scale score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of subjects with treatment-emergent adverse event or adverse drug reaction
Endpoint domain: Adverse events/effects
Primary endpoint: Number of subjects with clinically significant changes in hematology test result after injection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Maximum serum concentration (Cmax) of KMRC011
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: dynamic uptake and washout of 123-I CLINDE
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Stroke (Disabling) Rate
Endpoint domain: Mortality/survival
Primary endpoint: The Percentage of Subjects With None or Trace Prosthetic Regurgitation on Echocardiogram
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Peak VO2 output during exercise
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of faults in the cycling course
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Blood concentrations of the active metabolite of clopidogrel
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: SUVmax of 18F-FPPRGD2 uptake by lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Percent agreement of 18F-FPPRGD2 PET with pathology
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: general pain intensity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Intubation tube obstruction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Difference in SARS-CoV-2 infection
Endpoint domain: Adverse events/effects
Primary endpoint: One-year Survival
Endpoint domain: Mortality/survival
Primary endpoint: Hepatocellular Damage
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in cellulite
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants Achieving DAS28 Remission
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants Meeting the American College of Rheumatology 20% Response Criteria
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: The Change From Baseline of Clinical Disease Activity Index (CDAI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: The Change From Baseline of Simplified Disease Activity Index (SDAI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Overall Disease Severity Score (ODSS) for psoriasis vulgaris
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Phage-Neutralizing antibody titer
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Thyroid nodule size reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants Achieving PASI 100 Response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Proportion of patients achieving clinical response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cumulative incidence of treatment-related grade 2 or higher rectal bleeding
Endpoint domain: Adverse events/effects
Primary endpoint: Rate of newly diagnosed diabetes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change From Baseline to Day 57 in the Myasthenia Gravis - Activities of Daily Living (MG-ADL) Total Score
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Proportion of participants achieving target Pyoderma Gangrenosum Area Reduction (PGAR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Effective knowledge strategy
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Comparison of CSS readings to conventional carotid artery duplex ultrasound
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Number of Teens Using Any Alcohol During Past 6 Months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Frequency of Teen Alcohol Use Over Most Recent 30 Days Within Past 6 Months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Count of Teens Who Were Drunk or Very, Very High During the Past 6 Months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Severity of retinal axonal loss
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: complications after first-stage surgery
Endpoint domain: Adverse events/effects
Primary endpoint: local infection recurrence after first-stage surgery
Endpoint domain: Adverse events/effects
Primary endpoint: Insomnia Severity Index (Total)
Endpoint domain: Life impact
Endpoint subdomain: Sleep